No abstract

No abstract

The problem of direction of departure and direction of arrival estimation for multiple-input multiple-output (MIMO) radar is discussed, and a reduced-dimension Capon algorithm is derived. The proposed algorithm which only requires one-dimension search, can avoid the high computational cost within the two-dimension Capon (2D-Capon) algorithm. It is illustrated that the algorithm has slightly better performance than the 2D-Capon algorithm. Simulation results verify the usefulness of the algorithm.Introduction: Multiple-input multiple-output (MIMO) radar [1] utilises multiple antennas to simultaneously transmit diverse waveforms and receive the reflected signals in similar ways. Direction of departure (DOD) and direction of arrival (DOA) estimation algorithms for MIMO radar have been recently investigated in [2,3]. The two-dimension Capon (2D-Capon) algorithm [4] represents a possible implement for DOD and DOA estimation in MIMO radar; however, the requirement of two-dimension (2D) search renders much higher computational complexity. In this Letter, we derive a reduced-dimension Capon algorithm which distinctively reduces the complexity for angle estimation in a bistatic MIMO radar system. Notation: (.) T , (.) H and (.) 21 denote transpose, conjugate-transpose and matrix inverse operations, respectively. 0 I is an I × 1 vector of all zeros. I P is a P × P identity matrix.

No abstract

Background:Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC). Patients and methods: Eligible patients had stage IV nsq NSCLC without oncogenic drivers and had not received prior systemic cancer therapy. Treatment consisted of carboplatin/pemetrexed for up to 6 cycles followed by 21 cycles of pemetrexed maintenance or until progression or intolerance. Non-progression patients after two cycles of chemotherapy started to receive DCVAC/LuCa subcutaneously (s.c.) on day 15 of cycle 3, and thereafter q3w (day 15 of chemotherapy cycles) for up to 15 doses. Dosing of DCVAC/LuCa s.c. varied among patients depending on the baseline number of leucocytes but remained constant for each single patient. Safety was assessed by adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Efficacy was measured by overall survival (OS), progression-free survival (PFS), time to progression (TTP), and objective response rate (ORR).Results: Sixty-one patients were enrolled. In the safety population (n ¼ 60), eight patients (13.33%) had grade 3 or greater TRAEs, and six patients (10.0%) showed SAEs which were not related to leukapheresis or DC vaccination. Six grade 1 AEs were considered to be related to leukapheresis. No AESIs or DCVAC/LuCa-induced AEs were observed. The 2-year survival rate in the modified intention-to-treat population (n ¼ 44) was 52.57%. Median OS was not reached. Median PFS was 8.0 months, median TTP was 10.2 months, and the ORR was 31.82%. Conclusion:In treatment-naïve stage IV nsq NSCLC patients without oncogenic drivers, the combination of carboplatin/ pemetrexed and DCVAC/LuCa was well tolerated and showed promising efficacy. Therefore, a study to prove our immunotherapeutic concept in a randomized phase III trial is planned.